Three innovations pushing the medical field forward

Summary

---

Podcast Summary: Three Innovations Pushing the Medical Field Forward

Podcast: The Indicator from Planet Money (NPR)
Episode Date: August 18, 2025
Hosts: Darian Woods & Waylon Wong
Theme:
A concise exploration of three powerful medical innovations—each at a different stage of the innovation pipeline—unpacking their scientific promise and economic implications. The episode tours current breakthroughs, from cancer vaccines in early research to mass-market exoskeletons, examining what fuels innovation amid changing funding landscapes.

---

Overview

Darian Woods and Waylon Wong examine three selected medical breakthroughs, each illustrating a stage in medical innovation:

1. Early-stage research: A potential universal mRNA cancer vaccine (University of Florida)
2. Recent regulatory approval: A blood test diagnosing Alzheimer’s disease (Fuji Rabio Diagnostics, Japan)
3. Mass deployment/consumer tech: Affordable exoskeletons aiding mobility (Hypershell, China)

The discussion highlights each breakthrough’s economic context, funding, and prospects.

---

Key Discussion Points and Insights

1. Early Research: Universal mRNA Cancer Vaccine

• [02:24] Elias Sayer, pediatric oncologist and research lead at University of Florida, discusses his team’s new mRNA cancer vaccine.
• Cancer vaccines train an individual's immune system to target and remember cancer cells post-diagnosis, offering not just treatment but potentially improved long-term outcomes.
  • Sayer: “If you can educate the immune system to fight someone’s cancer, that immune system’s always there... It can do the same thing for cancer. So there’s so many advantages for not just treatment, but long-term care.” [02:46]
• Their key innovation: A “universal, generic” mRNA vaccine—instead of designing separate vaccines for every tumor type, their approach could work broadly (“first treatment in the future for all kinds of cancers”).
  • Sayer: “I’m hoping in the next three to five years we created a new paradigm for care.” [03:44]
• Caveat: Funding for mRNA research has recently been cut at the federal level.
  • Sayer: “There are a lot of threats to what we’re doing right now in terms of whether we can sustain this or not, honestly.” [04:18]

---

2. Recently Approved: Alzheimer’s Blood Test

• [04:26] Diana Dixon, VP at Fuji Rabio Diagnostics, outlines their rapid 2-year journey to FDA approval for an Alzheimer’s blood test.
  • Dixon: “It was, in my career, the fastest we’ve ever, ever done anything.” [04:42]
• Why this matters: Traditional Alzheimer’s diagnosis relies on expensive scans or invasive spinal taps; “100%” certainty only after death.
• Blood biomarkers now allow earlier, easier diagnosis, though results aren’t infallible.
  • Dixon: “...The answer is yes, the blood test isn’t perfect.” [05:35]
• The test’s commercial rollout is underway, bringing accessible screening to more patients.

---

3. Mass Deployment: Consumer-Grade Exoskeletons

• [06:13] Matt Ford (UK), a writer with severe rheumatoid arthritis, describes using the Hypershell exoskeleton (Chinese startup) to regain mobility—a product seen as “bionic bike shorts.”
• Cost: About $1,000, much cheaper than traditional medical mobility tech.
  • Ford: “Feels a little like being a puppet, though you’re in control at all times. The motor emits a whirr with each step... I then proceeded to walk around my house and garden, testing the settings with a huge grin on my face.” [07:52]
• Impact: His wheelchair is now “gathering dust”; uses exoskeleton for family outings and daily tasks.
• Exoskeletons aren’t new—the big shift is affordability, compactness, and user-friendliness.

---

Economics of Health Innovation: Who Funds What?

• [08:44] Wong: “All along the chain of innovation, you have different institutions involved with different incentives... For the fundamental research... government and universities and philanthropies fund that kind of work.”
• Multinationals like Fuji Rabio Diagnostics can commercialize, patent, and profit from mid-stage, validated technology (e.g., Alzheimer’s test).
• Agile startups are well-positioned to deliver affordable, consumer-focused innovations (e.g., Hypershell exoskeleton).

Woods: “Along the health innovation pipeline, each of those players have a role in improving living standards and our economy.” [09:25]

---

Notable Quotes & Memorable Moments

• Elias Sayer (re: universal mRNA cancer vaccine):
  “If you can educate the immune system to fight someone’s cancer, that immune system’s always there... So there’s so many advantages for not just treatment, but long-term care.” [02:46]

• Diana Dixon (on challenges diagnosing Alzheimer’s):
  “It’s a very, very tough disease to diagnose.” [05:11]

• Matt Ford (on using the Hypershell exoskeleton):
  “Feels a little like being a puppet, though you’re in control at all times.” [07:52]

• Waylon Wong (innovation pipeline):
  “All along the chain of innovation, you have different institutions involved with different incentives...” [08:44]

---

Timestamps for Key Segments

• 00:11 – Introduction: Growth and innovation in medical technology
• 02:24 – Segment 1: Universal mRNA cancer vaccine (early research)
• 04:26 – Segment 2: Alzheimer’s blood test (recent approval)
• 06:13 – Segment 3: Exoskeletons for mobility (mass deployment)
• 08:44 – Wrap-up: The economics and incentives of health innovation

---

Final Takeaway

This episode illustrates how medical breakthroughs aren’t just laboratory feats—they’re shaped by who invests, who regulates, and ultimately, who benefits. Across basic science, multinational commercialization, and nimble startups, progress in health technology is a complex, collaborative pipeline driving both better care and economic growth.

Transcript

[Announcer]

Npr.

[Darian Woods]

There are only a few ways to grow an economy. There's population growth. You can accumulate more capital, more machines and office blocks, but in the long run, you'll eventually reach limits. One of the most important ingredients for long term growth is better technology. And one area where innovation is happening fast right now is in medical technology.

[Waylon Wong]

Yeah, entire new therapies are being developed, whether it's new treatments for food allergies or CRISPR for gene editing. Each week it's as if we're getting news about GLP1s like Ozempic helping out in all kinds of areas seemingly unrelated to obesity. Like, did you know one study suggests it could fight breast cancer?

[Darian Woods]

I only just learned this. You know, soon it's going to be faster to list what GLP1s can't do. But today we're going to spotlight three medical advances that may have flown under the radar. This is the indicator from Planet Money. I'm Darian Woods.

[Waylon Wong]

And I'm Waylon Wong. Today on the show medical advances. As the federal government cuts science funding, we take you on a tour of the economics of health technology. We visit the University of Florida, a Japanese multinational and a Chinese startup.

[Capital One / Charles Schwab / Edward Jones Announcer]

This message comes from Capital One. With the Capital One Saver card, earn unlimited 3% cash back on dining and entertainment. Capital One what's in your wallet? Terms apply [e-mail] this message comes from Charles Schwab.

[Mint Mobile / LinkedIn Ads Announcer]

When it comes to managing your wealth, Schwab gives you more choices like full service, wealth management and advice when you need it. You can also invest on your own and trade on think or swim. Visit schwab.com to learn more support for NPR.

[Capital One / Charles Schwab / Edward Jones Announcer]

And the following message come from Edward Jones. What does it mean to live a rich life? Maybe it's full of brave first leaps, tearful goodbyes, and everything in between. And with over 100 years of experience, your Edward Jones financial advisor can help. EDWARD Jones Member, SIPC all right, we're.

[Darian Woods]

Going to go through three recent medical innovations and each will be on a stage along the pipeline. Early research, recent approval and mass deployment. First early research.

[Waylon Wong]

Elias Sayer is a pediatric oncologist and a physician scientist at the University of Florida. He and his team just released a paper on a cancer vaccine.

[Elias Sayer]

We think this is a groundbreaking discovery.

[Darian Woods]

Cancer vaccines work a little differently than regular vaccines. You take them after you've been diagnosed with cancer and it trains your body's immune system to destroy cancerous cells and stop them growing.

[Elias Sayer]

If you can educate the immune system to fight someone's cancer, that immune System's always there. Just like when it protects us against a virus and remembers it, it can do the same thing for cancer. So there's so many advantages for not just treatment, but long term care.

[Waylon Wong]

Cancer vaccines is this whole promising field of research. A lot of trials are using MRNA technology. MRNA vaccines work by getting your body to produce proteins that the immune system then learns to fight. By the way, they do not change your DNA.

[Darian Woods]

Yeah. Important clarification. MRNA vaccines do not genet modify you. So there are trials going on all over the world. But Elias's findings are special. His team made an MRNA vaccine that could fight a tumour. But unlike the other vaccines, they didn't have to formulate it to attack a specific tumour. They made kind of a universal generic vaccine that could be a first treatment in the future for all kinds of cancers.

[Elias Sayer]

I'm hoping in the next three to five years we created a new paradigm for care.

[Announcer]

Wow.

[Darian Woods]

Your hope is for an FDA approval essentially in three to five years?

[Announcer]

Yes. Wow. Yes.

[Waylon Wong]

That timeline might be optimistic given how MRNA research is under attack. Earlier this month, the Secretary of Health and Human Services, Robert F. Kennedy Jr. Cut $500 million from MRNA vaccine research. Because this cut was focused on infectious diseases, Elias doesn't think his work is affected directly, but he's still trying to figure out what this all.

[Elias Sayer]

There are a lot of threats to what we're doing right now in terms of whether we can sustain this or not, honestly.

[Darian Woods]

Next up, for an innovation that just achieved FDA approval, we turn now to a Japanese biotech company called Fuji Rabio Diagnostics. From concept to approval, Fuji Rabio Diagnostics spent a little less than two years working on a blood test for Alzheimer's disease.

[Diana Dixon]

It was, in my career, the fastest we've ever, ever done anything.

[Waylon Wong]

Diana Dixon is the vice president for clinical and regulatory sciences at the company. She says the FDA was particularly engaged with them because Alzheimer's is so Serious.

[Diana Dixon]

Right now, 7 million Americans are affected by this disease and we expect that to double within our lifetimes.

[Darian Woods]

One big problem at the moment is figuring out if someone with memory problems actually has Alzheimer's.

[Diana Dixon]

It's a very, very tough disease to diagnose.

[Waylon Wong]

Diana says the only 100% sure way to know is after someone passes away and their brain has buildup of this plaque, amyloid plaque. About 15 years ago, doctors started using brain scanners on live patients and then spinal taps to find evidence of that amyloid plaque. But those are expensive and require specialists.

[Diana Dixon]

And, you know, it's been several years of research with blood biomarkers to really see, can we do this? Can we get a blood test to replace or add to some of these tests that are hard to get to? And the answer is yes, the blood test isn't perfect.

[Darian Woods]

There is always the potential for false negatives and false positives, but along with other signs, it can give patients and their families a clearer picture of what's happening earlier. So now that they have approval, Fuji Rabio Diagnostics is onto the commercialisation phase. They're getting the blood tests out into the world.

[Waylon Wong]

And just because someone makes a breakthrough and it's approved doesn't mean that the medical solution is widely available or affordable. Take our third health innovation, exoskeletons. These are basically wearable robot suits that can make you stronger or walk faster. It could be an extension just for your arm or a brace like device just for walking.

[Darian Woods]

Matt Ford lives in the uk where he specializes in writing about historical weapons and armour. He has the autoimmune disease rheumatoid arthritis, which Dan damaged his joints and is now eroding his muscles. He didn't want to do a spoken conversation because of the way it affects his lungs, so we interviewed him over email.

[Waylon Wong]

Matt says that on his worst days, he's mostly confined to his bed. On good days he can walk, but not without pain and exhaustion. For a big day out, he uses a wheelchair, but says that's not without its problems, like stairs, uneven surfaces and the strength needed to propel it. Earlier this year, he saw an ad on social media showing an exoskeleton from a Chinese startup called Hyp, World's first.

[Darian Woods]

Multi scenario outdoor power suit. The Hypershell looks kind of like bionic bike shorts. It's these battery powered braces that help lift your thighs while you're walking.

[Waylon Wong]

Matt says it was about $1,000, a lot of money for him, but still way cheaper than other devices he's seen. He decided to take the plunge and ordered one straight from their website. Two weeks later, it arrived. After strapping it on with a heavy tap of haptic feedback, like a big phone vibration, the device prompted him that it was. We had a colleague read out how he described first using feels a little.

[Matt Ford]

Like being a puppet, though you're in control at all times. The motor emits a whirr with each step. I then proceeded to walk around my house and garden, testing the settings with a huge grin on my face.

[Darian Woods]

That sound you're hearing is Matt using the Hypershell. He says it's replaced his wheelchair, which is now gathering dust in his garage. He he uses the exoskeleton for family walks, long museum visits and shopping trips.

[Waylon Wong]

Now, exoskeletons aren't new. Some version of robotic assistants has been around since the 1960s. But what's changed is how compact they've gotten and how much the price has come down. Matt says he's excited to see how exoskeletons continue to progress.

[Darian Woods]

The type of innovation seen in exoskeletons is quite different to the MRNA cancer vaccine tests in a lab or the blood tests for Alzheimer's.

[Waylon Wong]

Yeah, and this reveals a pattern with innovation. All along the chain of innovation, you have different institutions involved with different incentives for the fundamental research that Elias is doing with cancer vaccines. That might be the kind of research where one company would struggle to recoup all its investments.

[Darian Woods]

So it makes sense that the government and universities and philanthropies fund that kind of work.

[Waylon Wong]

Exactly. And then you have the specific blood test for Alzheimer's that a big multinational like Fujiwo Diagnostics can support, patent and monetize. And when it comes to the consumer facing electronics of Hypershell, a private company has the nimbleness and incentives to be responsive to consumers and to source cheaper parts that can bring down costs all.

[Darian Woods]

Along the health innovation pipeline. Each of those players have a role in improving living standards and our economy. This episode was produced by Cooper Katz McKim with engineering by Robert Rodriguez. Voiceover was done by Greg Hartz. It was fact checked by Cyril Juarez. Cait Concannon edits the show and the indicator is a production event.

[Announcer]

PR.

[Mint Mobile / LinkedIn Ads Announcer]

This message comes from Mint Mobile. If you're tired of spending hundreds on big wireless bills, bogus fees and free perks, Mint Mobile might be right for you with plans starting from 15 bucks a month. Shop plans [e-mail] Switch upfront payment of $45 for 3 month 5GB plan required. New customer offer for first 3 months only. Then full price plan options available, taxes and fees extra. See Mint Mobile for detail. This Message comes from LinkedIn ads. Target your buyers by job title, company role and skills with LinkedIn ads. All the professionals you need to reach in one place get a $100 credit on your next [e-mail] results. Terms and conditions apply. This message comes from Mint Mobile. Mint Mobile took what's wrong with wireless and made it right. They offer premium wireless plans for less and all plans include high speed data, unlimited talk and text and nationwide coverage. See for [e-mail] Switch.